Brief: Bio-Path Holdings Announces Successful Completion Of Safety Cohort Of Triple Combination Of Prexigebersen, Decitabine And Venetoclax In Stage 2 Of Phase 2 Clinical Trial In Acute Myeloid Leukemia
05/04/2021 12:08
April 5 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF
SAFETY
COHORT OF TRIPLE COMBINATION OF PREXIGEBERSEN, DECITABINE AND
VENETOCLAX IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID
LEUKEMIA
Source text for Eikon: ID:nGNX4KCs3m
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia